Intrathecal injection of phenol (ITP) has been used to control intractable pain and spasticity. Direct caustic nerve damage has been postulated as the mechanism of analgesia. Sensation is commonly recovered, suggesting that a spontaneous regeneration process takes place. There is, however, a lack of mechanistic information on ITP therapy. To define morphologically the neurolysis and regeneration phenomena produced by ITP, anesthetized rats were subjected to laminectomy at L5; 5 microl of 22% phenol in saline solution or vehicle (control) was injected. Light and electron microscopy studies of nerve roots were performed at 2, 14, and 60 days after injection. Rats given ITP showed at the early stage a variable amount of roots with signs of infarction characterized by loss of axon-myelin units and thrombosis of intra-root vessels. At 14 days, abundance of macrophages removing debris, open vessels, and nerve sprouts was identified in damaged roots. At this time, non-myelinating glial fibrillary acidic protein-positive Schwann cells were observed in both damaged and apparently undamaged roots. At 60 days, abundance of 2',3'-cyclic nucleotide 3'-phosphodiesterase-positive Schwann cells myelinating newly formed axons was observed in damaged roots. Control rats did not show signs of neural or vascular pathology. Attempting to prevent thrombosis, another group of rats received heparin before ITP; these anti-coagulated rats developed radicular thrombosis, neurolysis, and hemorrhage. In conclusion, neurolysis produced by ITP is associated with acute ischemia (not prevented by heparin) and is followed by vascular, nerve, and myelin regeneration. Our results help understand the lack of efficacy of and some complications by ITP clinical therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1529-8027.2006.00103.x | DOI Listing |
Case Rep Hematol
December 2024
Department of Pathology and Laboratory Medicine, University of California Irvine (UCI) Medical Center, Orange, USA.
Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative neoplasm characterized by peripheral blood monocytosis and bone marrow dysplasia. In approximately one-fourth of cases, CMML can demonstrate progression to acute myeloid leukemia (AML), referred to as AML ex CMML. We present a 58-year-old woman with a past medical history of idiopathic thrombocytopenic purpura (ITP) who demonstrated 24% bone marrow blasts on a repeat biopsy obtained two years after being diagnosed with CMML.
View Article and Find Full Text PDFInt J Mol Sci
November 2024
Centre for Bioinnovation, University of the Sunshine Coast, Sippy Downs, QLD 4556, Australia.
RNA interference (RNAi)-based biotechnology has been previously implemented in decapod crustaceans. Unlike traditional RNAi methodologies that investigate single gene silencing, we employed a multigene silencing approach in decapods based on chimeric double-stranded RNA (dsRNA) molecules coined 'gene blocks'. Two dsRNA constructs, each targeting three genes of the crustacean hyperglycaemic hormone (CHH) superfamily of neuropeptides, were produced: Type II construct targeting Molt-inhibiting hormone 1 (MIH1), MIH-like 1 (MIHL1), and MIHL2 isoforms and Type I construct targeting ion transport peptide (ITP; a putative hybrid of CHH and MIH) and CHH and CHH-like (CHHL) isoforms.
View Article and Find Full Text PDFAnimals (Basel)
November 2024
CNRS, Integrative Center for Neuroscience and Cognition, INCC, UMR 8002, Université de Paris Cité, 75006 Paris, France.
It has been argued that domestication explains the ability of domestic animals to use human cues, but similar abilities exist in wild animals repeatedly exposed to humans. Little is known on the importance of the developmental stage of this exposure for developing such abilities. Orphancy and subsequent hand-rearing constitute a quasi-experimental situation for investigating this question.
View Article and Find Full Text PDFAnn Hematol
November 2024
Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Recombinant human thrombopoietin (rhTPO) is commonly used to improve low platelet status in immune thrombocytopenia (ITP), as one protein product, even with a very low rate, there is still the possibility to produce neutralizing antibodies of thrombopoietin (TPO). We described a 7-year-old boy with ITP and normal TPO levels who had previously received rhTPO for 2 weeks but showed persistent thrombocytopenia and was misdiagnosed as acquired amegakaryocytic thrombocytopenia (AATP) and ineffectively treated with cyclosporine A (CsA) in combination with avatrombopag (AVA). As suspicious the TPO neutralizing antibody development as re-test of TPO level is 0, the CD20 + deletion antibody drug rituximab (RTX) was prescribed and received efficacy.
View Article and Find Full Text PDFZhongguo Shi Yan Xue Ye Xue Za Zhi
October 2024
Department of Hematology, Shenzhen Hospital of Southern Medical University, Shenzhen 518100, Guangdong Province, China.
Primary immune thrombocytopenia (ITP) is an autoimmune disease characterized by thrombocytopenia, and T cell immune dysfunction plays an important role in the formation of ITP. As a thrombopoietin receptor agonist (TPO- RA), eltrombopag can not only directly stimulate megakaryocytes to produce platelets, but also play an immunomodulatory role by inducing regulatory T cell generation and reducing proinflammatory factors. As a second-line treatment drug for adult ITP, eltrombopag is increasingly widely used in clinical practice.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!